SecBot SecBot
S-3ASR ·Filed Apr 28, 2026

CDNA

CareDx, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed6mo ago SEC0001104659-26-050471
Notable filing: S-3ASR
Actionable Insight • Neutral

Monitor for future prospectus supplements that will disclose actual offering size, pricing, and terms. The concurrent Naveris acquisition suggests capital may be raised to fund the deal. The shelf itself is a routine financing tool, but actual offerings could be dilutive. Watch for insider selling patterns and any subsequent 8-K filings detailing a specific offering.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$20.80
T+0 close · Apr 28, 2026 · via day close
Latest settled
+78.56%
T+60 · $37.14
Vs SPY
+74.45%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 29 $20.80entry
  2. T+1 · 7mo ago 0.00%α −1.02% · $20.80
  3. T+5 · 7mo ago −0.48%α −3.59% · $20.70
  4. T+20 · 6mo ago +6.54%α +1.08% · $22.16
  5. T+60 · 4mo ago +78.56%α +74.45% · $37.14
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CareDx filed an automatic shelf registration (S-3ASR) on April 28, 2026, concurrently with the announcement of its Q1 2026 earnings and the acquisition of Naveris, Inc. The shelf allows for the issuance of an indeterminate amount of common stock, preferred stock, debt securities, warrants, subscription rights, and units. No specific offering size or pricing is disclosed; registration fees are deferred under Rule 457(r). The filing provides financial flexibility to fund the Naveris acquisition and for general corporate purposes, but introduces potential future dilution.

Key Facts

  • Filed automatic shelf registration (S-3ASR) on April 28, 2026, concurrent with Q1 2026 earnings and Naveris acquisition announcement.
  • Registration covers an indeterminate amount of common stock, preferred stock, debt securities, warrants, subscription rights, and units.
  • Registration fees are deferred under Rule 457(r); no initial offering size or pricing is specified.
  • Proceeds, if any, will be used for working capital, general corporate purposes, and potentially to support acquisitions like Naveris.
  • The shelf provides financial flexibility but introduces potential future dilution for existing shareholders.
  • Q1 2026 results and the Naveris acquisition are detailed in concurrently filed 10-Q and 8-K, providing context for the capital need.

Financial Impact

Undisclosed; no specific offering size or pricing provided in the filing.

dilutiondebt

Risk Factors

  • Potential dilution from future equity or convertible debt offerings under the shelf.
  • Increased leverage if debt securities are issued.
  • Execution risk related to the integration of Naveris acquisition.

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories
Analyst Consensus
60% bullish (15 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
S-3ASR Filing (Primary)0001104659-26-050471
Document: tm2612370d2_ex4-2.htm0001104659-26-050471
Document: tm2612370d1_ex-filingfees.htm0001104659-26-050471
Document: tm2612370d2_ex4-3.htm0001104659-26-050471

US Market Status

Market Closed · Opens Wed (9h 53m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 28, 2026